Sareum Holdings plc

LSE SAR.L

Sareum Holdings plc Net Cash Used Provided By Financing Activities for the year ending June 30, 2024: USD 5.54 M

Sareum Holdings plc Net Cash Used Provided By Financing Activities is USD 5.54 M for the year ending June 30, 2024. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Sareum Holdings plc Net Cash Used Provided By Financing Activities for the year ending June 30, 2022 was USD 4.51 M, a 31.02% change year over year.
Sareum Holdings plc Net Cash Used Provided By Financing Activities for the year ending June 30, 2021 was USD 3.45 M, a 63.92% change year over year.
Sareum Holdings plc Net Cash Used Provided By Financing Activities for the year ending June 30, 2020 was USD 2.10 M, a 106.15% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

LSE: SAR.L

Sareum Holdings plc

CEO	Dr. Stephen Barry Parker DPhil, M.B.A., Ph.D.
IPO Date	Oct. 11, 2004
Location	United Kingdom
Headquarters	Langford Arch
Employees	5
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals

Description

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

Key trends

Past 5 years